Wire · operational-macro
FDA grants accelerated approval to GSK's lung cancer drug
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
The US FDA granted accelerated approval to GSK's drug for patients with an advanced form of lung cancer whose disease progressed after earlier treatments.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You just gained a new route to market for lung cancer treatment in the US. Start planning trials or partnerships to leverage this faster approval track while competitors adjust.
◆ Coverage
1 source · 17 Nov 2026
◆ Related on Wire
◆ Topics
Biotechfda-approvallung-canceraccelerated-approvalgskoncology